Healthy Clinical Trial
Official title:
Collection of Whole Blood to be Used to Provide the Safety and Effectivenss of a Lyme Disease Diagnostic Assay to Support the Proposed Intended Use Statement and Product Labeling Claims.
Verified date | February 2024 |
Source | DiaSorin Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The primary objective is to obtain whole blood from subjects with signs and/or symptoms of early Borrelisois. Whole blood will also be obtained from subjects with suspicion of acute Borreliosis and under medical examination for Lyme disease. In addition, whole blood will be obtained from apparently healthy subjects residing in areas endemic to Lyme disease and may also inlclude apparently healthy subjects residing in areas non-endemic to Lyme disease.
Status | Enrolling by invitation |
Enrollment | 450 |
Est. completion date | December 31, 2024 |
Est. primary completion date | December 30, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | N/A and older |
Eligibility | Subjects with under evaluation of Lyme Disease Inclusion Criteria: Signs and symptoms of acute Lyme disease which include at least one of the following: - Recent onset of fatigue - Skin rash - Fever - Muscle aches - Neck pain - Joint pain or lymphadenopathy Subgroup Borreliosis Subjects- restricted signs and symptoms of acute Lyme including EM Rash - Under physician or medical evaluation for acute on-set of Lyme Disease presenting with EM Rash - Detailed description of the EM rash (e.g. Itchy, painful, hot, vesicular, raised) with consent for photographic documentation is required including additional picture with ruler placing to confirming size. - EM rash with the following attributes: - Size > 5 cm in diameter - Appeared 3-30 days after bite or suspected bite - Specify Location (e.g. underarm or back of knee) - Subjects with confirmed early localized or disseminated Lyme Borreliosis manifestation - Signs and symptoms (e.g. Fever, Chills/Sweats, Headache, Fatigue/Tiredness, Myalgia/Sore muscles) - The EM rash has been present <42 days - Clinical diagnosis of Lyme disease is suspected by the practitioner - Ability to provide the minimum sample volume required Exclusion Criteria: - Subjects unable to provide informed consent. - Subjects without clinical information and/or not meeting inclusion criteria. - Subjects having started antibiotic treatment > 5 days before inclusion. Healthy Subjects Inclusion Criteria: - Apparently healthy subjects with no present fever, chills, headache, fatigue, muscle and joint aches, and swollen lymph nodes, e.g. flu-like symptoms. - Ability to provide the minimum sample volume required. Exclusion Criteria: - ? Subjects unable to provide informed consent - Subjects without clinical information and/or not meeting inclusion criteria - Subjects with a recent diagnosis of Lyme disease, Anaplasmosis, Babesiosis, or history of known embedded tick bite which may have required 'manual extraction' NOTE: a tick just found on the subject or presence of a crawling tick is not considered a 'tick bite') - Subjects currently on antibiotic treatment. - Uncontrolled HIV-infection, if known. This is defined as an HIV-1 viral load >40 copies/mL and/or CD4+ count <500 x 106 cells/liter in the past 12 months. - Active syphilis or leptospirosis, if known - Active infection with Epstein Barr Virus (mononucleosis), if known - Active infection with Cytomegalovirus (CMV), if known - Subjects with autoimmune diseases, either confirmed rheumatoid arthritis and/or other autoimmune disorders diagnosed according to the leading guidelines - Current immunomodulation mediation including >7.5 mg prednisone daily, methotrexate, and/or biologicals. Medications such as hydroxychloroquine, sulfasalazine or NSAIDs are acceptable. - Immunodeficiency, hematologic malignancies in the medical history - Chemotherapy during the past year |
Country | Name | City | State |
---|---|---|---|
United States | DiaSorin Inc. | Stillwater | Minnesota |
Lead Sponsor | Collaborator |
---|---|
DiaSorin Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Clinical Performance - Sensitivity | Diagnostic Sensitivity | Through study completion, an average of 1 year | |
Secondary | Clinical Performance - Specificity | Diagnostic Specificity | Through study completion, an average of 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |